Skip to content
HowShorted

Nektar Therapeutics short interest in 2024

In 2024, Nektar Therapeutics's disclosed short interest ran from 2.85% of shares outstanding on 12 Jan 2024 to 2.36% on 31 Dec 2024, a change of -0.49 percentage points. The year's high was 5.30% on 15 Jul 2024 and its low 1.05% on 29 Feb 2024, averaging 2.72% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.31 days on 30 Aug 2024. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2024

2024 in figures

Start of year
2.85% (12 Jan 2024)
End of year
2.36% (31 Dec 2024)
Change
-0.49 pp
High
5.30% (15 Jul 2024)
Low
1.05% (29 Feb 2024)
Average
2.72%
Highest days to cover
10.31 (30 Aug 2024)
SEC filings marked
9

Every report in 2024

Nektar Therapeutics short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20242.85%6.07results (8-K)
31 Jan 20243.04%9.15
15 Feb 20241.29%1.55
29 Feb 20241.05%1.50
15 Mar 20241.32%1.00results (8-K), 10-K filed
28 Mar 20241.24%2.38
15 Apr 20241.63%1.00
30 Apr 20241.86%1.88
15 May 20241.44%1.54results (8-K), 10-Q filed
31 May 20241.49%1.60
14 Jun 20242.36%3.12
28 Jun 20242.20%1.00
15 Jul 20245.30%5.60
31 Jul 20244.81%8.71
15 Aug 20244.60%8.16results (8-K), 10-Q filed
30 Aug 20244.48%10.31
13 Sep 20244.22%10.23
30 Sep 20243.97%7.78
15 Oct 20243.28%5.20
31 Oct 20242.84%3.60
15 Nov 20242.78%2.33results (8-K), 10-Q filed
29 Nov 20242.41%2.39
13 Dec 20242.38%1.67
31 Dec 20242.36%3.49

See also: Nektar Therapeutics's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.